Anti-Inflammatory Effects of β-Cryptoxanthin on 5-Fluorouracil-Induced Cytokine Expression in Human Oral Mucosal Keratinocytes. 2023

Hironaka Yamanobe, and Kenta Yamamoto, and Saki Kishimoto, and Kei Nakai, and Fumishige Oseko, and Toshiro Yamamoto, and Osam Mazda, and Narisato Kanamura
Department of Dental Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.

Oral mucositis is a typical adverse effect of chemotherapy, causing oral pain that significantly reduces the patient's quality of life. β-cryptoxanthin (β-cry) is a carotenoid abundant in citrus fruits with antioxidant and anti-inflammatory effects. However, the β-cry effect on oral mucositis remains unclear. We investigated the effects of 5-fluorouracil (5-FU) and β-cry on human normal oral mucosal keratinocytes (hOMK). hOMK was seeded on a culture plate and cultured with 5-FU and β-cry. The cell number, mRNA expression of inflammatory cytokines and matrix metalloproteinases (MMPs), and production of inflammatory cytokines in hOMK were evaluated. Additionally, the cell count and inflammatory cytokine production were analyzed when hOMK was co-stimulated with Porphyromonas gingivalis lipopolysaccharide (P. gingivalis LPS) in addition to 5-FU. The numbers of hOMK significantly reduced with 5-FU stimulation, whereas it increased with β-cry treatment. mRNA expression of interleukin (IL)-6, IL-8, metalloproteinase (MMP)-2, and MMP-9 and protein production of IL-6 and IL-8 in hOMK were augmented on 5-FU stimulation. Simultaneously, β-cry treatment significantly suppressed IL-8 and MMP-9 mRNA expression, and IL-8 production was induced on 5-FU stimulation. Co-stimulation with P. gingivalis LPS and 5-FU enhanced IL-6 and IL-8 production in hOMK. β-cry could enhance cell proliferation and suppress 5-FU-induced expression of inflammatory cytokines and MMP in hOMK. Thus, β-cry can alleviate the symptoms of chemotherapy-induced oral mucositis, and its combination with oral care is effective in managing oral mucositis.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072743 Beta-Cryptoxanthin A mono-hydroxylated xanthophyll that is a provitamin A precursor. Beta Cryptoxanthin
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D013280 Stomatitis INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP. Oral Mucositis,Mucositis, Oral,Oromucositis,Mucositides, Oral,Oral Mucositides,Oromucositides,Stomatitides
D015603 Keratinocytes Epidermal cells which synthesize keratin and undergo characteristic changes as they move upward from the basal layers of the epidermis to the cornified (horny) layer of the skin. Successive stages of differentiation of the keratinocytes forming the epidermal layers are basal cell, spinous or prickle cell, and the granular cell. Keratinocyte
D015850 Interleukin-6 A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS. Hepatocyte-Stimulating Factor,Hybridoma Growth Factor,IL-6,MGI-2,Myeloid Differentiation-Inducing Protein,Plasmacytoma Growth Factor,B Cell Stimulatory Factor-2,B-Cell Differentiation Factor,B-Cell Differentiation Factor-2,B-Cell Stimulatory Factor 2,B-Cell Stimulatory Factor-2,BSF-2,Differentiation Factor, B-Cell,Differentiation Factor-2, B-Cell,IFN-beta 2,IL6,Interferon beta-2,B Cell Differentiation Factor,B Cell Differentiation Factor 2,B Cell Stimulatory Factor 2,Differentiation Factor 2, B Cell,Differentiation Factor, B Cell,Differentiation-Inducing Protein, Myeloid,Growth Factor, Hybridoma,Growth Factor, Plasmacytoma,Hepatocyte Stimulating Factor,Interferon beta 2,Interleukin 6,Myeloid Differentiation Inducing Protein,beta-2, Interferon

Related Publications

Hironaka Yamanobe, and Kenta Yamamoto, and Saki Kishimoto, and Kei Nakai, and Fumishige Oseko, and Toshiro Yamamoto, and Osam Mazda, and Narisato Kanamura
January 1999, ORL; journal for oto-rhino-laryngology and its related specialties,
Hironaka Yamanobe, and Kenta Yamamoto, and Saki Kishimoto, and Kei Nakai, and Fumishige Oseko, and Toshiro Yamamoto, and Osam Mazda, and Narisato Kanamura
November 2021, Journal of clinical biochemistry and nutrition,
Hironaka Yamanobe, and Kenta Yamamoto, and Saki Kishimoto, and Kei Nakai, and Fumishige Oseko, and Toshiro Yamamoto, and Osam Mazda, and Narisato Kanamura
January 2021, Antioxidants (Basel, Switzerland),
Hironaka Yamanobe, and Kenta Yamamoto, and Saki Kishimoto, and Kei Nakai, and Fumishige Oseko, and Toshiro Yamamoto, and Osam Mazda, and Narisato Kanamura
April 2016, Reproductive toxicology (Elmsford, N.Y.),
Hironaka Yamanobe, and Kenta Yamamoto, and Saki Kishimoto, and Kei Nakai, and Fumishige Oseko, and Toshiro Yamamoto, and Osam Mazda, and Narisato Kanamura
January 2014, PloS one,
Hironaka Yamanobe, and Kenta Yamamoto, and Saki Kishimoto, and Kei Nakai, and Fumishige Oseko, and Toshiro Yamamoto, and Osam Mazda, and Narisato Kanamura
January 2022, Journal of applied oral science : revista FOB,
Hironaka Yamanobe, and Kenta Yamamoto, and Saki Kishimoto, and Kei Nakai, and Fumishige Oseko, and Toshiro Yamamoto, and Osam Mazda, and Narisato Kanamura
September 2001, Oral oncology,
Hironaka Yamanobe, and Kenta Yamamoto, and Saki Kishimoto, and Kei Nakai, and Fumishige Oseko, and Toshiro Yamamoto, and Osam Mazda, and Narisato Kanamura
August 2009, European journal of pharmacology,
Hironaka Yamanobe, and Kenta Yamamoto, and Saki Kishimoto, and Kei Nakai, and Fumishige Oseko, and Toshiro Yamamoto, and Osam Mazda, and Narisato Kanamura
April 2023, International journal of molecular sciences,
Hironaka Yamanobe, and Kenta Yamamoto, and Saki Kishimoto, and Kei Nakai, and Fumishige Oseko, and Toshiro Yamamoto, and Osam Mazda, and Narisato Kanamura
July 2013, Archives of oral biology,
Copied contents to your clipboard!